Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Eye (Lond) ; 2024 Jun 21.
Artículo en Inglés | MEDLINE | ID: mdl-38907015

RESUMEN

PURPOSE: To investigate the postoperative clinical outcomes and axial length (AL) growth of infants with congenital cataracts and microphthalmos following first-stage cataract surgery. DESIGN: Retrospective case-control study. METHODS: Setting: Single centre. Infants with congenital cataract that met the inclusion criteria were classified into two groups: the microphthalmos and comparison groups. All infants underwent a thorough ophthalmologic examination before surgery, and one week, 1 month, 3 months, and every 3 months after surgery. RESULTS: This study enrolled 21 infants (42 eyes) in the microphthalmos group and 29 infants (58 eyes) in the comparison group. More glaucoma-related adverse events were observed in the microphthalmos group (7 eyes, 16.7%) than in the comparison group (0 eyes, 0%) (p < 0.001). At each subsequent follow-up, the comparison group had a greater AL than the microphthalmos group (all p < 0.001), and AL growth was significantly higher in the comparison group than in the microphthalmos group (all p = 0.035). Visual acuity improvement in the microphthalmos group was similar to that of the comparison group. CONCLUSION: Early surgical intervention improves visual function in infants with congenital cataracts and microphthalmos although with a higher incidence of glaucoma-related adverse events. After cataract removal, the AL growth of microphthalmic eyes is slower than that of normally developed eyes.

2.
Ophthalmol Ther ; 13(6): 1527-1535, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38581607

RESUMEN

INTRODUCTION: The aim of this work is to investigate the dynamic changes of capsular-intraocular lens (IOL) adhesion in plate-haptic hydrophilic and loop-haptic hydrophobic eyes. METHODS: Cataract eyes that met the inclusion criteria were randomly assigned to receive implantation of a plate-haptic hydrophilic or loop-haptic IOL. The anterior capsular adhesion, posterior capsular adhesion, and the configurations of the capsular bend were evaluated using swept-source optical coherence tomography at 1 day, 1 week, 1 month, and 3 months postoperatively. RESULTS: In total, 66 eyes of 66 patients were eligible for the analysis: 33 in the plate-haptic group and 33 in the loop-haptic group. The contact between the anterior capsule and IOL in the plate-haptic group was earlier than that in the loop-haptic group upon comparing the measurements taken at 1 day and 1 week (p = 0.001, p = 0.003, respectively). The complete attachment of the posterior capsule and IOL in the plate-haptic group was significantly greater at 1 week, 1 month, and 3 months (p = 0.001, p = 0.000, p = 0.001, respectively). The capsular bend index of the plate-haptic group was significantly greater than that of the loop-haptic group at each time points except at 1 day (p = 0.007, p = 0.049, p = 0.005, respectively). Furthermore, a new type of capsular bend, "cocked adhesion," was observed in the plate-haptic eyes. CONCLUSIONS: The plate-haptic IOL demonstrated excellent capsular adhesion compared to the loop-haptic IOL, which was probably attributed to haptic compressibility. A special cocked configuration of the capsular bend in plate-haptic IOL was observed for the first time. Further studies are warranted to confirm the effect of the new type of capsular bend.

3.
J Refract Surg ; 39(10): 705-710, 2023 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-37824298

RESUMEN

PURPOSE: To evaluate the accuracy of newer online intraocular lens (IOL) formulas in extremely elongated eyes (axial length > 30 mm). METHODS: This retrospective case series study included 236 patients (236 eyes). Postoperative refractive outcomes of the Barrett Universal II (BU II), Cooke K6 (K6), Emmetropia Verifying Optical (EVO) 2.0, Hoffer QST (HQST), Kane, Pearl-DGS, and Radial Basis Function (RBF) 3.0 formulas were compared. Subgroup analysis was performed in the extreme myopia group 1 (30 < axial length ≤ 32 mm), extreme myopia group 2 (32 < axial length ≤ 35 mm), and meniscus IOL group. The root mean square absolute prediction error (RMSAE) and proportions of eyes of prediction errors within ±0.50 diopters (D) were calculated for statistical analysis. RESULTS: For the extreme myopia group 1, RBF 3.0 achieved the lowest RMSAE (0.361) and EVO 2.0 showed the highest proportion of eyes within ±0.50 diopters (85.06%). For the extreme myopia group 2, the RMSAE of the K6 (0.442) and EVO 2.0 (0.475) was significantly lower than the BU II (0.610), Kane (0.641), and HQST (0.759, P ≤ .016) formulas. In the meniscus IOL group, the K6 formula showed the lowest RMSAE (0.402) and the highest percentage within ±0.50 diopters (84.31%). CONCLUSIONS: The EVO 2.0 and K6 formulas are recommended for IOL power calculation in eyes with extreme myopia. Modern artificial intelligence-based formulas should be used cautiously when the axial length is longer than 32 mm or meniscus IOLs are implanted. [J Refract Surg. 2023;39(10):705-710.].


Asunto(s)
Lentes Intraoculares , Miopía , Facoemulsificación , Humanos , Estudios Retrospectivos , Inteligencia Artificial , Biometría , Refracción Ocular , Miopía/cirugía , Óptica y Fotónica , Longitud Axial del Ojo
4.
Ophthalmol Ther ; 12(3): 1583-1594, 2023 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-36856976

RESUMEN

INTRODUCTION: This study analyzed the visual outcome following cataract surgery with toric intraocular lenses (IOLs) in patients older than 80 years with corneal astigmatism. METHODS: A total of 159 patients (159 eyes) older than 80 years with corneal astigmatism (≥ 0.75 D) were included. Fifty-three eyes received Acrysof IQ® toric IOLs (SN6AT2-5), while the others received non-toric IOLs: 51 eyes received Acrysof IQ® IOLs (SN60WF) and 55 eyes received A1-UV IOLs. The uncorrected distance visual acuity, corrected distance visual acuity, and refraction (spherical equivalent, refractive cylinder) were assessed at 3 months postoperatively. The prediction error of refractive outcome and percentages of eyes within ± 0.50 D and ± 1.00 D in the toric IOL group obtained using five toric IOL formulas (Barrett predicted posterior corneal astigmatism (PCA), Barrett measured PCA, Kane, EVO 2.0 and Næser-Savini) were compared. RESULTS: At 3 months postoperatively, the average uncorrected distance visual acuity was better in the toric IOL group than the non-toric IOL group (p < 0.001). The mean residual refractive cylinder was lower in the toric IOL group than the non-toric IOL group (p < 0.001). The Næser-Savini formula achieved the lowest mean absolute error (0.39 D) and had the highest percentages of eyes within an absolute error of 0.50 D and 1.00 D (72% and 98%) compared to the other formulas. CONCLUSION: The results demonstrate the efficacy of toric IOL implantation in patients older than 80 years with corneal astigmatism and provide strong evidence for cataract surgeons to encourage such patients to choose toric IOLs.

5.
Graefes Arch Clin Exp Ophthalmol ; 261(1): 127-135, 2023 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-35802204

RESUMEN

PURPOSE: To investigate the characteristics of eyes with large variations in predicted refraction using four traditional intraocular lens (IOL) formulas and evaluate the accuracy of new-generation intraocular lens power calculation formulas. METHODS: Eyes that had variation in predicted refraction (≥ 0.75 D) using four traditional formulas (SRK/T, Holladay 1, Hoffer Q, and Haigis formulas) were included. Axial length (AL), anterior chamber depth (ACD), average keratometry (AK), and the ratio of axial length to corneal radius (AL/CR) were measured. New-generation formulas (Barrett Universal II, Emmetropia Verifying Optical 2.0, Kane, and Pearl-DGS formulas) and traditional formulas were compared. The median absolute error (MedAE) was the main parameter to evaluate the accuracy of formulas. RESULTS: A total of 79 participants (79 eyes) who had variation in predicted refraction of (≥ 0.75 D) using four traditional formulas out of 510 eyes (510 patients) underwent uncomplicated cataract surgeries. The Barrett Universal II (0.29 D), EVO 2.0 (0.31 D), Kane (0.30 D), and Pearl-DGS (0.33 D) formulas produced significantly lower median absolute errors (MedAEs) than the Hoffer Q (0.61 D) and Holladay 1 (0.59 D) formulas (P < 0.01). The Wang-Koch (WK) adjustment significantly improved the accuracy of the Holladay 1 formula in long eyes (P < 0.001). CONCLUSIONS: Abnormal AL, ACD, and AK are more likely to lead to prediction errors using traditional formulas. New-generation formulas and traditional formulas with WK adjustment showed satisfactory prediction accuracy.


Asunto(s)
Lentes Intraoculares , Facoemulsificación , Humanos , Agudeza Visual , Implantación de Lentes Intraoculares , Refracción Ocular , Pruebas de Visión , Biometría , Estudios Retrospectivos , Óptica y Fotónica , Longitud Axial del Ojo
6.
Zhonghua Yan Ke Za Zhi ; 51(10): 730-3, 2015 Oct.
Artículo en Chino | MEDLINE | ID: mdl-26693766

RESUMEN

The studies and clinical applications of Ranibizumab and Bevacizumab which are new anti-VEGF drugs have made significant progression on the treatment of corneal neovascularization. The effectiveness and safety of Ranibizumab compared with Bevacizumab has been the focus of the debate for scholars nowadays. Some experiments showed that the effect of Bevacizumab was better than Ranibizumab. But combined with our experiments, Ranibizumab represented the advantages of shorter effect time, stronger affinity with VEGF-A, better tolerance with repeated injections etc. So we believed that the adequate doses of ranibizumab had better effects. Its clinical application should be paid much attention.


Asunto(s)
Inhibidores de la Angiogénesis/uso terapéutico , Bevacizumab/uso terapéutico , Neovascularización de la Córnea/tratamiento farmacológico , Ranibizumab/uso terapéutico , Factor A de Crecimiento Endotelial Vascular/antagonistas & inhibidores , Inhibidores de la Angiogénesis/efectos adversos , Anticuerpos Monoclonales Humanizados , Bevacizumab/efectos adversos , Humanos , Ranibizumab/efectos adversos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...